Vitti Long Haul conducts long haul covid clinical trials to evaluate stem cell and exosome-based therapies designed to repair lung tissue, reduce inflammation, and improve respiratory health. Their innovative VL-PX10 and VL-P22 formulations are progressing through advanced clinical stages, offering promising results for patients with lingering post-COVID complications.
Mesenchymal Stem Cells Therapy for Pulmonary Fibrosis
Advancing research into pulmonary fibrosis through innovative clinical trials, Vitti Long Haul explores mesenchymal stem cells therapy, which focuses on reducing lung inflammation, supporting tissue regeneration, and slowing disease progression. This science-driven approach investigates how stem cells and their bioactive factors may help repair damaged lung tissue and improve outcomes for patients with fibrotic lung conditions.
Write a comment ...